Glossary of Terms
CKB News Archive
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit
and sign-up for CKB BOOST.
Check out the Bio-IT World commentary on JAX-CKB!
JAX-CKB now includes
for gene variants.
Interested in learning more about JAX-CKB?
Check out this video!
Thank you, Bio-IT World! JAX-CKB receives an honorable mention for the 2018 Best Practices Awards!
Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at